September 5, 2011
Kuniaki Natsume, senior operating officer, Otsuka Holdings (HD), recently revealed that Otsuka aims to launch the oral anticancer drug TS-1 (tegafur + gimeracil + oteracil potassium) in Europe in the second quarter of 2012 (proposed brand name: Teysuno). A joint...read more